Multimodality Treatments in Metastatic Gastric Cancer

Gastric cancer represents one of the most frequent and lethal tumors worldwide today, finding itself in the fifth place in incidence and the third in mortality. Surgery remains the only curative treatment for localized tumors, but only 20% of patients are suitable for surgery due to the lack of spec...

Full description

Saved in:
Bibliographic Details
Sonstige:
Year of Publication:2021
Language:English
Physical Description:1 electronic resource (162 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
id 993545482304498
ctrlnum (CKB)5400000000041993
(oapen)https://directory.doabooks.org/handle/20.500.12854/77077
(EXLCZ)995400000000041993
collection bib_alma
record_format marc
spelling Petrillo, Angelica edt
Multimodality Treatments in Metastatic Gastric Cancer
Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021
1 electronic resource (162 p.)
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
Gastric cancer represents one of the most frequent and lethal tumors worldwide today, finding itself in the fifth place in incidence and the third in mortality. Surgery remains the only curative treatment for localized tumors, but only 20% of patients are suitable for surgery due to the lack of specific symptoms and the late diagnosis, especially in Western countries. Additionally, even in patients who receive curative treatment, rates of locoregional relapse and distant metastasis remain high. Palliative chemotherapy is the principal treatment in cases of metastatic disease even if the prognosis of patients receiving chemotherapy is still poor. Therefore, a multidisciplinary evaluation is important in order to improve the efficacy of active treatments. In this context, there is an unmet need for a better understanding of genetic alterations and prognostic and predictive factors in order to choose the best tailored therapy for each patient. The aim of this Special Issue is to focus on the results and problems of multimodality treatment in metastatic gastric cancer, the search for prognostic and predictive factors, and the evaluation of novel strategies for individualized treatment. We are inviting relevant original research, systematic reviews, meta-analyses, and short communications covering the above-mentioned topics.
English
Medicine bicssc
advanced gastric cancer
precision medicine
new drug development
gastro-oesophageal cancer
mutational concordance
exome sequencing
formalin fixed paraffin embedded
biomarkers
gastric cancer
metastatic
body composition
sarcopenia
visceral fat area
subcutaneous fat area
outcome
toxicity
liver metastasis
conversion surgery
hepatectomy
stage iv gastric cancer
immune checkpoint inhibitors
Epstein Barr Virus
tumor mutational burden
microsatellite instability
predictive biomarkers
CAR T cell therapy
vaccines
nutritional status
metastatic gastric cancer
target therapy
bone flare
stage IV
treatment
RANK-L
liquid biopsy
circulating tumor cell
cfDNA
ctDNA
epithelial-mesenchymal transition
resistance to treatment
HER2-inhibition
VEGFR-inhibition
immunotherapy
response monitoring
3-0365-2592-0
3-0365-2593-9
Petrillo, Angelica oth
language English
format eBook
author2 Petrillo, Angelica
author_facet Petrillo, Angelica
author2_variant a p ap
author2_role Sonstige
title Multimodality Treatments in Metastatic Gastric Cancer
spellingShingle Multimodality Treatments in Metastatic Gastric Cancer
title_full Multimodality Treatments in Metastatic Gastric Cancer
title_fullStr Multimodality Treatments in Metastatic Gastric Cancer
title_full_unstemmed Multimodality Treatments in Metastatic Gastric Cancer
title_auth Multimodality Treatments in Metastatic Gastric Cancer
title_new Multimodality Treatments in Metastatic Gastric Cancer
title_sort multimodality treatments in metastatic gastric cancer
publisher MDPI - Multidisciplinary Digital Publishing Institute
publishDate 2021
physical 1 electronic resource (162 p.)
isbn 3-0365-2592-0
3-0365-2593-9
illustrated Not Illustrated
work_keys_str_mv AT petrilloangelica multimodalitytreatmentsinmetastaticgastriccancer
status_str n
ids_txt_mv (CKB)5400000000041993
(oapen)https://directory.doabooks.org/handle/20.500.12854/77077
(EXLCZ)995400000000041993
carrierType_str_mv cr
is_hierarchy_title Multimodality Treatments in Metastatic Gastric Cancer
author2_original_writing_str_mv noLinkedField
_version_ 1796651990763175936
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03729nam-a2200817z--4500</leader><controlfield tag="001">993545482304498</controlfield><controlfield tag="005">20231214133456.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202201s2021 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000041993</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/77077</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000041993</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Petrillo, Angelica</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Multimodality Treatments in Metastatic Gastric Cancer</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel, Switzerland</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2021</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (162 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Gastric cancer represents one of the most frequent and lethal tumors worldwide today, finding itself in the fifth place in incidence and the third in mortality. Surgery remains the only curative treatment for localized tumors, but only 20% of patients are suitable for surgery due to the lack of specific symptoms and the late diagnosis, especially in Western countries. Additionally, even in patients who receive curative treatment, rates of locoregional relapse and distant metastasis remain high. Palliative chemotherapy is the principal treatment in cases of metastatic disease even if the prognosis of patients receiving chemotherapy is still poor. Therefore, a multidisciplinary evaluation is important in order to improve the efficacy of active treatments. In this context, there is an unmet need for a better understanding of genetic alterations and prognostic and predictive factors in order to choose the best tailored therapy for each patient. The aim of this Special Issue is to focus on the results and problems of multimodality treatment in metastatic gastric cancer, the search for prognostic and predictive factors, and the evaluation of novel strategies for individualized treatment. We are inviting relevant original research, systematic reviews, meta-analyses, and short communications covering the above-mentioned topics.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">advanced gastric cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">precision medicine</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">new drug development</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gastro-oesophageal cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mutational concordance</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">exome sequencing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">formalin fixed paraffin embedded</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biomarkers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">gastric cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metastatic</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">body composition</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sarcopenia</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">visceral fat area</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">subcutaneous fat area</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">outcome</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">toxicity</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">liver metastasis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">conversion surgery</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">hepatectomy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">stage iv gastric cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune checkpoint inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Epstein Barr Virus</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor mutational burden</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">microsatellite instability</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">predictive biomarkers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">CAR T cell therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">vaccines</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nutritional status</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metastatic gastric cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">target therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">bone flare</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">stage IV</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">treatment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">RANK-L</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">liquid biopsy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">circulating tumor cell</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">cfDNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">ctDNA</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">epithelial-mesenchymal transition</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">resistance to treatment</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HER2-inhibition</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">VEGFR-inhibition</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">response monitoring</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-2592-0</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-2593-9</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Petrillo, Angelica</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:55:07 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&amp;portfolio_pid=5337927260004498&amp;Force_direct=true</subfield><subfield code="Z">5337927260004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337927260004498</subfield></datafield></record></collection>